PD-1 and PD-L1 Inhibitors – Market Outlook, Competitive Landscape, Treatment Utilization, and Market Forecast Report – 2026 To 2036

PD-1 and PD-L1 Inhibitors Market Outlook and Forecast

Thelansis’s “PD-1 and PD-L1 Inhibitors Market Outlook, Competitive Landscape, Treatment Utilization, and Market Forecast Report – 2026 To 2036” offers a comprehensive view of competitive positioning, treatment utilization, and revenue potential as these therapies move across multiple lines of therapy and disease indications over the 2026-2036 forecast period across eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

PD-1 and PD-L1 Inhibitors Overview

PD-1 and PD-L1 inhibitors are immune checkpoint therapies that block inhibitory signals tumors exploit to suppress T-cell activity, allowing the immune system to mount a stronger antitumor response. They have become the most clinically validated and commercially established class of cancer immunotherapies, underpinning treatment across numerous tumor types. The category is approaching a major competitive transition as key U.S. patent and regulatory-exclusivity cliffs emerge from 2028 onward, creating the prospect of biosimilar competition for foundational products such as pembrolizumab and nivolumab. The transition is unlikely to be instantaneous, however, as patent litigation, regulatory requirements, interchangeability, contracting, and physician adoption will influence the pace of biosimilar uptake. Manufacturers are already responding with more convenient formulations: FDA-approved subcutaneous pembrolizumab with berahyaluronidase alfa (Keytruda Qlex) in 2025 across the solid-tumor indications of intravenous pembrolizumab. At the same time, competition is shifting toward novel combinations, differentiated delivery, and next-generation immune checkpoints. For stakeholders, PD-1/PD-L1 illustrates how a mature blockbuster class can enter a new competitive cycle without losing its central role in oncology.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• What is the current market size and what are the projected growth trajectories for PD-1 and PD-L1 inhibitors across G8 markets through 2036?
• Which geographic markets are driving PD-1/PD-L1 adoption, and how do market dynamics differ across the US, EU5, Japan, and China?
• Who are the key competitive players and market leaders, and how are they positioned across therapeutic indications, lines of therapy, and formulation strategies?
• What are the primary clinical, commercial, and regulatory drivers reshaping the PD-1/PD-L1 market, and what constraints could impede growth?
• How large is the treatable patient population across indications, and what is the current treatment utilization rate by line of therapy and geographic market?
• What is the expected market impact of emerging therapies, novel combinations, and next-generation checkpoints, and which late-stage pipeline products pose competitive threats?
• What are the unmet clinical needs in PD-1/PD-L1 treatment, and what target product profiles (TPP) do physicians and payers expect from next-generation checkpoint inhibitors?
• What regulatory approvals, reimbursement requirements, and market access strategies are essential to compete effectively across the G8 markets?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)